Literature DB >> 17666895

HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma.

Tomas Hucl1, Marja-Leena Kylanpää-Bäck, Heiko Witt, Beat Künzli, Marko Lempinen, Alexander Schneider, Esko Kemppainen, Matthias Löhr, Helmut Friess, Johann Ockenga, Jonas Rosendahl, Hans-Ulrich Schulz, Thomas Gress, Manfred V Singer, Roland H Pfützer.   

Abstract

PURPOSE: The homozygous p.C282Y variant of the HFE gene is a major risk factor for hereditary hemochromatosis, a disorder of iron metabolism resulting in progressive iron accumulation in a variety of organs including the pancreas. Heterozygosity of p.C282Y and p.H63D may increase susceptibility to chronic liver and pancreatic disease. This study determines the frequencies of p.C282Y and p.H63D alterations in patients with chronic pancreatitis and pancreatic adenocarcinoma.
METHODS: In total, 958 patients (349 with alcoholic pancreatitis, 343 with idiopathic pancreatitis, 64 with familial chronic pancreatitis, 34 with acute pancreatitis, and 168 with pancreatic adenocarcinoma) were enrolled and compared with 681 healthy and 100 alcoholic controls. Furthermore, 45 parent-offspring trios were included for segregation analysis. Genotyping of p.C282Y and p.H63D was performed by restriction fragment length polymorphism or melting curve analyses.
RESULTS: No significant differences were found in heterozygosity for p.C282Y and p.H63D when patients with alcoholic (8.0/21.5%), idiopathic (7.3/24.5%), or familial (9.8/23.0%) pancreatitis, or pancreatic adenocarcinoma (5.4/28.6%) were compared with healthy (6.2/24.8%) and alcoholic (7.0/25.0%) controls. Neither genotype was associated with the presence of secondary diabetes mellitus in patients with chronic pancreatitis.
CONCLUSION: Although hemochromatosis is associated with pancreatic pathology, the p.C282Y and p.H63D variants do not play a significant role in the pathogenesis of chronic pancreatitis or pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666895     DOI: 10.1097/gim.0b013e3180986df4

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  4 in total

1.  Plasma ferritin levels, HFE polymorphisms, and risk of pancreatic cancer among Chinese Han population.

Authors:  Zhiming Zhao; Chenggang Li; Minggeng Hu; Jidong Li; Rong Liu
Journal:  Tumour Biol       Date:  2014-05-06

2.  The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.

Authors:  Yang-Fan Lv; Xian Chang; Rui-Xi Hua; Guang-Ning Yan; Gang Meng; Xiao-Yu Liao; Xi Zhang; Qiao-Nan Guo
Journal:  J Cell Mol Med       Date:  2016-02-19       Impact factor: 5.310

3.  Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Authors:  Antonio Agudo; Catalina Bonet; Núria Sala; Xavier Muñoz; Núria Aranda; Ana Fonseca-Nunes; Françoise Clavel-Chapelon; Marie Christine Boutron-Ruault; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Sara Grioni; J Ramón Quirós; Esther Molina; Carmen Navarro; Aurelio Barricarte; Saioa Chamosa; Naomi E Allen; Kay-Tee Khaw; H Bas Bueno-de-Mesquita; Peter D Siersema; Mattijs E Numans; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Rudof Kaaks; Federico Canzian; Heiner Boeing; Karina Meidtner; Mattias Johansson; Malin Sund; Jonas Manjer; Kim Overvad; Anne Tjonneland; Eiliv Lund; Elisabete Weiderpass; Mazda Jenab; Veronika Fedirko; G Johan A Offerhaus; Elio Riboli; Carlos A González; Paula Jakszyn
Journal:  Carcinogenesis       Date:  2013-02-06       Impact factor: 4.944

Review 4.  Iron Metabolism in Cancer Progression.

Authors:  Stefania Forciniti; Luana Greco; Fabio Grizzi; Alberto Malesci; Luigi Laghi
Journal:  Int J Mol Sci       Date:  2020-03-24       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.